DURHAM, N.C., Feb. 14, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available broad spectrum antiviral therapeutics, today announced the completion of a $45 million Series F financing. New Leaf Venture Partners led the round, with participation by new investors Pappas Ventures and Morningside Group, as well as existing investors Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Company and Frazier Healthcare Ventures.
Proceeds from this financing will be used to support the development of Chimerix's two clinical-stage candidates, CMX001 and CMX157. CMX001 is in clinical development as a broad spectrum antiviral for the treatment of life-threatening viral infections in immunocompromised patients, and has a potential dual use as a medical countermeasure in the event of a smallpox release. Chimerix is evaluating CMX001 in an ongoing Phase 2 clinical study of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients, and in an Open-Label Study under an expanded access protocol for the treatment of critically-ill patients with any of 12 different double-stranded DNA viral infections. A Phase 2 clinical trial of CMX001 in pediatric and adult hematopoietic stem cell transplant patients with adenovirus related diseases is currently being initiated. Chimerix recently completed a Phase 1 clinical trial of CMX157, a potent nucleoside analogue in development for the treatment of HIV infections, including those caused by multi-drug resistant viruses.
"Development of our two clinical-stage antiviral therapeutics is rapidly accelerating. We are truly pleased to receive this strong support from leading life science investors for Chimerix's ground-breaking programs," said Kenneth I. Moch, President and CEO of Chimerix. "We are extremely enthusiastic about the very real prospects for Chimerix's drugs to dramatically improve the treatment of deadly viral infections."<
|SOURCE Chimerix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved